Manufacturer of Controlled Substances; Notice of Application, 49315-49316 [E7-16937]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 166 / Tuesday, August 28, 2007 / Notices
49315
200 new taxpayers will complete ATF F
5630.7 in its entirety in approximately
15 minutes. The total number of
respondents for this information
collection is 3,000.
(6) An estimate of the total public
burden (in hours) associated with the
collection: The total burden for ATF F
5630.5R and ATF F 5630.5RC is 933
hours. The total burden for ATF F
5630.7 is 50 hours. The estimated total
public burden associated with this
information collection is 983 hours.
If additional information is required
contact: Lynn Bryant, Department
Clearance Officer, Policy and Planning
Staff, Justice Management Division,
Department of Justice, Patrick Henry
Building, Suite 1600, 601 D Street, NW.,
Washington, DC 20530.
Schedule
pwalker on PROD1PC71 with NOTICES
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection: ATF
F 5630.5R, NFA Special Tax Renewal
Registration and Return, ATF F
5630.5RC, NFA Special Tax Location
Registration Listing, ATF F 5630.7, NFA
Special Tax Registration and Return
National Firearms Act.
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Form Number: ATF F
5630.5R, ATF F 5630.5RC, ATF F
5630.7. Bureau of Alcohol, Tobacco,
Firearms and Explosives.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Business or other forprofit. Other: None. ATF F 5630.7, NFA
Special Tax Registration and Return
National Firearms Act is completed and
returned by businesses that are subject
to Special Occupation Taxes under the
National Firearms Act for either initial
tax payment or business information
changes. This form serves as both a
return and a business registration. ATF
F 5630.5R, NFA Special Tax Renewal
Registration and Return and ATF F
5630.5RC, NFA Special Tax Location
Registration Listing are preprinted forms
sent to taxpayers who Special
Occupational Taxes under the National
Firearms Act. Taxpayers validate/
correct the information and send the
forms back with payment for the
applicable tax year.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 2,800
taxpayers will complete forms ATF F
5630.5R and ATF F 5630.5RC in
approximately 20 minutes (10 minutes
for each form). It is also estimated that
VerDate Aug<31>2005
19:52 Aug 27, 2007
Jkt 211001
Dated: August 22, 2007.
Lynn Bryant,
Department Clearance Officer, PRA,
Department of Justice.
[FR Doc. E7–16969 Filed 8–27–07; 8:45 am]
BILLING CODE 4410–FY–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 20, 2007,
Cerilliant Corporation, 811 Paloma
Drive, Suite A, Round Rock, Texas
78664, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Aminorex (1585) ...........................
4-Methylaminorex (cis isomer)
(1590).
Gamma
Hydroxybutyric
acid
(2010).
Methaqualone (2565) ...................
Alpha-Ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Drug
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
N-Hydroxy-3,4methylendioxyamphetamine
(7402).
3,4-Methylendioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Benzylmorphine (9052) ................
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Hydromorphinol (9301) .................
Methyldihydromorphine (9304) .....
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Pholcodine (9314) ........................
Acetylmethadol (9601) .................
Allylprodine (9602) .......................
Alphacetylmethadol except levoalphacetylmethadol (9603).
Alphameprodine (9604) ................
Alphamethadol (9605) ..................
Betacetylmethadol (9607) ............
Betameprodine (9608) ..................
Betamethadol (9609) ....................
Betaprodine (9611) .......................
Hydroxypethidine (9627) ..............
Noracymethadol (9633) ................
Norlevorphanol (9634) ..................
Normethadone (9635) ..................
Trimeperidine (9646) ....................
Phenomorphan (9647) .................
Para-Fluorofentanyl (9812) ..........
3-Methylfentanyl (9813) ................
Alpha-Methylfentanyl (9814) ........
Acetyl-alpha-methylfentanyl
(9815).
Beta-hydroxyfentanyl (9830) ........
Beta-hydroxy-3-methylfentanyl
(9831).
Alpha-Methylthiofentanyl (9832) ...
3-Methylthiofentanyl (9833) ..........
Thiofentanyl (9835) ......................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Phenmetrazine (1631) ..................
Methylphenidate (1724) ................
Ambobarbital (2125) .....................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
E:\FR\FM\28AUN1.SGM
28AUN1
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
49316
Federal Register / Vol. 72, No. 166 / Tuesday, August 28, 2007 / Notices
Schedule
Drug
1-Piperidinocyclohexane
carbonitrile (8603).
Alphaprodine (9010) .....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Isomethadone (9226) ...................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Racemethorphan (9732) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
DEPARTMENT OF JUSTICE
II
Drug Enforcement Administration
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
[Docket No. 07–36]
Spirit Pharmaceuticals, L.L.C., c/o
Novelty, Inc; Denial of Request for
Hearing
II
II
II
II
II
II
II
II
II
pwalker on PROD1PC71 with NOTICES
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537; or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 JeffersonDavis Highway, Alexandria, Virginia
22301; and must be filed no later than
October 29, 2007.
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–16937 Filed 8–27–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
19:52 Aug 27, 2007
Jkt 211001
On June 22, 2007, I, the Deputy
Administrator of the Drug Enforcement
Administration, issued an Order to
Suspend Shipment to Spirit
Pharmaceuticals, L.L.C., of Fairless
Hills, Pennsylvania. See 21 U.S.C.
971(c). The Order suspended Spirit’s
proposed importation of 2,000
kilograms of Ephedrine Hydrochloride
to be purchased from Emmellen Biotech
Pharmaceuticals, LTD., of Mumbai,
India. Order at 1.
The factual basis of the Order was that
Spirit, a registered importer, had
identified AAA Pharmaceuticals, Inc.
(AAA), as the customer, on the Import
Declaration (DEA Form 486) that it filed.
Id. at 2. DEA personnel subsequently
contacted AAA and determined that the
ephedrine was to be used to
manufacture tablets that would be sold
to Novelty, Inc. Id. at 2.
The Order related that ephedrine is a
list I chemical, which while having a
legitimate use as a bronchodilator, is
also a precursor chemical which is used
in the illicit manufacture of
methamphetamine, a schedule II
controlled substance. Id. The Order also
related that DEA has found that nontraditional (or gray-market) retailers,
which include such entities as gas
stations, convenience stores, minimarts, and liquor stores, ‘‘purchase and
sell ephedrine * * * OTC products in
quantities that exceed what would be
necessary to meet legitimate demand’’ at
these establishments, and that the
products ‘‘are often sold to persons for
use in the illicit manufacture of
methamphetamine.’’ Id. Finally, the
Order related that ‘‘AAA manufactures
and Novelty distributes’’ ephedrine
products which are ‘‘not widelyadvertised and are distributed to ‘nontraditional’ retail outlets * * * such as
convenience stores and gas stations.’’ Id.
at 3. Based on DEA’s experience with
similar ephedrine products which were
distributed to non-traditional retailers, I
found that ‘‘the proposed importation of
ephedrine may be diverted to the
clandestine manufacture of controlled
substances.’’ Id.
The Order notified Spirit that it could
request a hearing by filing a written
request within thirty days of its receipt
of the Order, and that if it failed to do
so, it would be deemed to have waived
its right to a hearing. Id. Spirit did not,
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
however, request a hearing. Nor did
AAA.
Instead, on July 5, 2007, Novelty filed
a request for a hearing asserting that it
is ‘‘a regulated person to whom an order
applies’’ under 21 U.S.C. 971(c)(2). ALJ
Memorandum at 1; see also Ltr. of
Novelty’s Counsel (June 28, 2007), at 1.
Novelty also contended that it ‘‘is
directly harmed, both in its property
and liberty interests,’’ and that it ‘‘has
an independent due process right to a
hearing under the Fifth Amendment
* * * regardless of whether Spirit also
requests a hearing on the order of
suspension.’’ Ltr. of Novelty’s Counsel
at 1. Id.
Upon receipt of Novelty’s letter, the
matter was assigned to Administrative
Law Judge (ALJ) Gail Randall, who
initiated pre-hearing procedures.
Shortly thereafter, the Government filed
a motion to deny Novelty a hearing on
various grounds including that it is a
downstream distributor and thus not
entitled to a hearing under the statute.
See Mot. to Deny Novelty, Inc. an
Adjudicatory Hearing Under 21 U.S.C.
971(c)(2) (hereinafter, Mot. to Deny).
Upon review of the Government’s
motion, the ALJ concluded ‘‘that the
usual manner of handling an
administrative hearing is not
appropriate here.’’ ALJ Memorandum at
2. Noting that ‘‘[t]he entity asking for a
hearing, Novelty, is not the entity
addressed in the Order to Suspend
Shipment, Spirit Pharmaceuticals,’’ and
that the Government had objected to
granting Novelty a hearing on the
validity of the suspension order, the ALJ
concluded that ‘‘the designation of this
matter for a hearing is not clear.’’ Id.
The ALJ thus transmitted the issue to
me for resolution. Id. at 2–3.
For the reasons set forth below, I
conclude that Novelty is not ‘‘a
regulated person to whom an order
applies under [21 U.S.C. 971(c)(1)].’’ 21
U.S.C. 971(c)(2). Accordingly, I deny
Novelty’s request for a hearing to
challenge the suspension order. I further
order that the proceedings currently
pending before the ALJ be terminated.
Discussion
Under 21 U.S.C. 971(a), ‘‘[e]ach
regulated person who imports * * * a
listed chemical shall notify the Attorney
General of the importation * * * not
later than 15 days before the transaction
is to take place.’’ (emphasis added).1 In
1 In subsection (b), Congress directed that the
Attorney General issue regulations ‘‘for
circumstances in which the requirement of
subsection (a) * * * does not apply to a transaction
between a regulated person and a regular customer
or to an importation by a regular importer.’’ 21
U.S.C. 971(b)(1).
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 72, Number 166 (Tuesday, August 28, 2007)]
[Notices]
[Pages 49315-49316]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16937]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 20, 2007, Cerilliant
Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made
application by renewal to the Drug Enforcement Administration (DEA) for
registration as a bulk manufacturer of the basic classes of controlled
substances listed in schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
Aminorex (1585)............................ I
4-Methylaminorex (cis isomer) (1590)....... I
Gamma Hydroxybutyric acid (2010)........... I
Methaqualone (2565)........................ I
Alpha-Ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
3,4,5-Trimethoxyamphetamine (7390)......... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
5-Methoxy-3,4-methylenedioxyamphetamine I
(7401).
N-Hydroxy-3,4-methylendioxyamphetamine I
(7402).
3,4-Methylendioxy-N-ethylamphetamine (7404) I
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
Alpha-methyltryptamine (7432).............. I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
Acetyldihydrocodeine (9051)................ I
Benzylmorphine (9052)...................... I
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Heroin (9200).............................. I
Hydromorphinol (9301)...................... I
Methyldihydromorphine (9304)............... I
Morphine-N-oxide (9307).................... I
Normorphine (9313)......................... I
Pholcodine (9314).......................... I
Acetylmethadol (9601)...................... I
Allylprodine (9602)........................ I
Alphacetylmethadol except levo- I
alphacetylmethadol (9603).
Alphameprodine (9604)...................... I
Alphamethadol (9605)....................... I
Betacetylmethadol (9607)................... I
Betameprodine (9608)....................... I
Betamethadol (9609)........................ I
Betaprodine (9611)......................... I
Hydroxypethidine (9627).................... I
Noracymethadol (9633)...................... I
Norlevorphanol (9634)...................... I
Normethadone (9635)........................ I
Trimeperidine (9646)....................... I
Phenomorphan (9647)........................ I
Para-Fluorofentanyl (9812)................. I
3-Methylfentanyl (9813).................... I
Alpha-Methylfentanyl (9814)................ I
Acetyl-alpha-methylfentanyl (9815)......... I
Beta-hydroxyfentanyl (9830)................ I
Beta-hydroxy-3-methylfentanyl (9831)....... I
Alpha-Methylthiofentanyl (9832)............ I
3-Methylthiofentanyl (9833)................ I
Thiofentanyl (9835)........................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Phenmetrazine (1631)....................... II
Methylphenidate (1724)..................... II
Ambobarbital (2125)........................ II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Glutethimide (2550)........................ II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
[[Page 49316]]
1-Piperidinocyclohexane carbonitrile (8603) II
Alphaprodine (9010)........................ II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Hydrocodone (9193)......................... II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Isomethadone (9226)........................ II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Racemethorphan (9732)...................... II
Alfentanil (9737).......................... II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances to make reference standards which will be
distributed to their customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537; or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be filed no later than October 29,
2007.
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-16937 Filed 8-27-07; 8:45 am]
BILLING CODE 4410-09-P
